This “Paranasal sinus cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 5-10 companies and 5-10 pipeline drugs in Paranasal sinus cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Paranasal sinus cancer is a disease in which malignant tumor cells form in the tissues of paranasal sinuses and nasal cavity. The cancer can begin in the cells of membrane, bone, or nerves in the open spaces behind the nose. It is a type of head and neck cancer. Most common type of paranasal sinus cancer is squamous cell carcinoma. Being exposed to certain chemicals or dust deliberately increases the chances for developing paranasal sinus cancer.
Symptoms can include blocked sinuses, pain in sinus areas, nosebleeds, lump inside the nose that does not heal, and swelling or other trouble with the eyes, such as double vision or the eyes pointing in different directions.
Diagnosing Paranasal sinus cancer requires physical assessments of nose, face, and neck. Furthermore, clinicians also recommend screening procedures such as X-rays, MRI, CT scan, nasoscopy, laryngoscopy to view inside the nose for abnormal areas. Sometimes biopsy is also done to detect the presence of malignant cells inside the sinus cavity.
Different types of treatments are available for patients with paranasal sinus cancer. The currently used treatments include surgery, radiation therapy, and chemotherapy which comprises of administration of several approved drugs such as cisplatin, docetaxel, methotrexate, and others.
This segment of the Paranasal sinus cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cabozantinib: Exelixis
Exelixis' lead drug candidate, Cabozantinib, is an orally administered small molecule receptor tyrosine kinase inhibitor that inhibits specific tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2 and suppress metastases, and oncogeneses. Preclinical data demonstrated that Cabozantinib is used for the treatment of head and neck as well as paranasal sinus squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery.
Motolimod: Celgene
Celgene drug motolimod is currently being evaluated for the treatment of Paranasal sinus cancer. Motolimod, a toll-like receptor 8 (TLR8) agonist, stimulates myeloid dendritic cells, monocytes, and natural killer cells in the blood and tumor microenvironment, inducing a proinflammatory immune response. In the phase I trial, Tumor immune modulation will be evaluated by counting the number of tumor infiltration CD8+ T cells before and after treatment.
There are approx. 10+ key companies which are developing the therapies for Paranasal sinus cancer. The companies which have their Paranasal sinus cancer drug candidates in the mid to advanced stage, i. e. phase III and Phase II include, Exelixis and others.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Paranasal sinus cancer therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Paranasal sinus cancer drugs.
Geography Covered
- Global coverage
Paranasal sinus cancer Understanding
Paranasal sinus cancer: Overview
Paranasal sinus cancer is a disease in which malignant tumor cells form in the tissues of paranasal sinuses and nasal cavity. The cancer can begin in the cells of membrane, bone, or nerves in the open spaces behind the nose. It is a type of head and neck cancer. Most common type of paranasal sinus cancer is squamous cell carcinoma. Being exposed to certain chemicals or dust deliberately increases the chances for developing paranasal sinus cancer.
Symptoms
Symptoms can include blocked sinuses, pain in sinus areas, nosebleeds, lump inside the nose that does not heal, and swelling or other trouble with the eyes, such as double vision or the eyes pointing in different directions.
Diagnosis
Diagnosing Paranasal sinus cancer requires physical assessments of nose, face, and neck. Furthermore, clinicians also recommend screening procedures such as X-rays, MRI, CT scan, nasoscopy, laryngoscopy to view inside the nose for abnormal areas. Sometimes biopsy is also done to detect the presence of malignant cells inside the sinus cavity.
Treatment
Different types of treatments are available for patients with paranasal sinus cancer. The currently used treatments include surgery, radiation therapy, and chemotherapy which comprises of administration of several approved drugs such as cisplatin, docetaxel, methotrexate, and others.
Paranasal sinus cancer Emerging Drugs Chapters
This segment of the Paranasal sinus cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Paranasal sinus cancer Emerging Drugs
Cabozantinib: Exelixis
Exelixis' lead drug candidate, Cabozantinib, is an orally administered small molecule receptor tyrosine kinase inhibitor that inhibits specific tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2 and suppress metastases, and oncogeneses. Preclinical data demonstrated that Cabozantinib is used for the treatment of head and neck as well as paranasal sinus squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery.
Motolimod: Celgene
Celgene drug motolimod is currently being evaluated for the treatment of Paranasal sinus cancer. Motolimod, a toll-like receptor 8 (TLR8) agonist, stimulates myeloid dendritic cells, monocytes, and natural killer cells in the blood and tumor microenvironment, inducing a proinflammatory immune response. In the phase I trial, Tumor immune modulation will be evaluated by counting the number of tumor infiltration CD8+ T cells before and after treatment.
Paranasal sinus cancer: Therapeutic Assessment
This segment of the report provides insights about the different Paranasal sinus cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Paranasal sinus cancer
There are approx. 10+ key companies which are developing the therapies for Paranasal sinus cancer. The companies which have their Paranasal sinus cancer drug candidates in the mid to advanced stage, i. e. phase III and Phase II include, Exelixis and others.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Paranasal sinus cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Cutaneous
- Subcutaneous
- Intravenous
- Oral
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Paranasal sinus cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Paranasal sinus cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Paranasal sinus cancer drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Paranasal sinus cancer R&D. The therapies under development are focused on novel approaches to treat/improve Paranasal sinus cancer.
Paranasal sinus cancer Report Insights
- Paranasal sinus cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Paranasal sinus cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Paranasal sinus cancer drugs?
- How many Paranasal sinus cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Paranasal sinus cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Paranasal sinus cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Paranasal sinus cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Exelixis
- Bristol-Myers Squibb
- Eli Lily
- S. L.A. Pharma AG
- Celgene
Key Products
- Cabozantinib
- Motolimod
- Metronidazole
- Nivolumab
Table of Contents
IntroductionExecutive Summary
Paranasal sinus cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Paranasal sinus cancer - Analytical Perspective
In-depth Commercial Assessment
- Paranasal sinus cancer companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Paranasal sinus cancer Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
- Comparative Analysis
Cabozantinib: Exelixis
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Motolimod: Celgene
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Paranasal sinus cancer Key Companies
Paranasal sinus cancer Key Products
Paranasal sinus cancer- Unmet Needs
Paranasal sinus cancer- Market Drivers and Barriers
Paranasal sinus cancer- Future Perspectives and Conclusion
Paranasal sinus cancer Analyst Views
Paranasal sinus cancer Key Companies
AppendixList of Tables
Table 1 Total Products for Paranasal sinus cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Paranasal sinus cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Exelixis
- Bristol-Myers Squibb
- Eli Lily
- S.L.A. Pharma AG
- Celgene
